Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1994 Jun;4(6):449-61.
doi: 10.2165/00002512-199404060-00002.

Polypharmacy in the aged. Practical solutions

Affiliations
Review

Polypharmacy in the aged. Practical solutions

R B Stewart et al. Drugs Aging. 1994 Jun.

Abstract

Elderly patients use more medications than younger patients and the trend of increasing drug use continues through 80 years of age. Studies conducted in a variety of settings have shown that patients over 65 years of age use an average of 2 to 6 prescribed medications and 1 to 3.4 non-prescribed medications. Success of pharmaceutical and medical research has resulted in an abundance of effective drugs to treat acute and chronic conditions. Most research resulting in the development and marketing of these medications has been directed at proving the efficacy and safety of single drug products. Little research has been directed to determine the safety and efficacy of combining multiple medications to treat concurrent conditions in a single patient. It is known that the use of multiple medications increases the risks of adverse drug reactions, drug-drug interactions, and makes compliance with medication regimens more difficult. Numerous studies have been conducted to better understand factors that are associated with increased drug use in elderly people. Studies also have been conducted to identify interventions that can improve drug treatment for the elderly, and reduce polypharmacy. Multiple drug use is common in older people, and may give rise to drug related problems. Methods to reduce the risks of polypharmacy include patient education, physician education, such as education and feedback systems, and regulatory intervention. Continual drug and disease monitoring is essential.

PubMed Disclaimer

References

    1. Med Care. 1984 Mar;22(3):193-201 - PubMed
    1. N Engl J Med. 1990 Jan 25;322(4):239-48 - PubMed
    1. N Engl J Med. 1983 Jun 16;308(24):1457-63 - PubMed
    1. Lancet. 1988 Jul 2;2(8601):20-2 - PubMed
    1. Can Med Assoc J. 1979 Oct 20;121(8):1074-81 - PubMed

Substances

LinkOut - more resources